This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Joan Stephenson, PhD

JAMA. 2001;285:2067-2068.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

New research findings involving a tried-and-true antibiotic developed decades ago are pointing the way toward a novel approach for treating genetic disorders in the 21st century, researchers suggest.

In one recent study, investigators at the University of Alabama at Birmingham (UAB) found evidence that gentamicin treatment enabled cells from patients with Hurler syndrome to override the effects of the mutation underlying the disease (Hum Mol Genet. 2001:10:291-299).

Furthermore, a growing body of research by the UAB group and others indicates that drugs such as gentamicin may one day be used to treat a subset of patients with a variety of genetic disorders, such as cystic fibrosis and muscular dystrophy. Although clinical trials testing gentamicin or agents with similar properties are at least a few years off, researchers say that laboratory and animal studies, as well as some pilot studies in human subjects, suggest that the . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Translational readthrough by the aminoglycoside geneticin (G418) modulates SMN stability in vitro and improves motor function in SMA mice in vivo
Heier and DiDonato
Hum Mol Genet 2009;18:1310-1322.
ABSTRACT | FULL TEXT